Latest news and press releases about Biofrontera Inc. (BFRI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Price
| Price | $1.24 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.78 |
| EV / EBITDA | -4.17 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -127.78% |
| Return on Invested Capital | -31.18% |
| Return on Assets | -26.45% |
| Gross Margin | 84.45% |
| Operating Margin | -9.45% |
| Net Margin | -13.78% |
Related companies: AYTU · COCP · DWTX · EVGN · GELS · IMNN · PRPH
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of BFRI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks